Cargando…
Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver
Combination platinum-based therapy has been the standard of care for the treatment of advanced non-small-cell lung cancer (NSCLC). Immunotherapy has emerged and demonstrated to show benefit in the treatment of patients with advanced NSCLC. In this review, we discuss the pivotal trials that led to th...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Future Medicine Ltd
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7399613/ https://www.ncbi.nlm.nih.gov/pubmed/32774467 http://dx.doi.org/10.2217/lmt-2020-0003 |